Balla Cristina, Cappato Riccardo
Cardiovascular Center, University of Ferrara, Ferrara, Italy.
Department of Biomedical Sciences, Humanitas Clinical Research Institute, Humanitas University, Milan, Italy.
Eur Heart J Suppl. 2019 Mar;21(Suppl B):B31-B35. doi: 10.1093/eurheartj/suz026. Epub 2019 Mar 29.
Cardiac resynchronization therapy (CRT) is an established treatment for patients with heart failure (HF), impaired left ventricular (LV) function, and wide QRS complex. The initial randomized clinical trials, which led to the widespread use of CRT, selected patients on the basis of QRS duration, not focusing on QRS morphology. However, recent evidences emphasized the role of left bundle branch block morphology in patients that underwent CRT in order to predict better response to therapy. Moreover, conventional right ventricular apical pacing might have long-term detrimental effects on cardiac structure and LV function, possibly leading to the development of HF. Therefore, current guidelines recommend upgrade from conventional pacemaker or implantable cardioverter-defibrillator to CRT or CRT in patients with high (or expected high) percentage of ventricular pacing and reduced EF. We reviewed current knowledge on candidates' selection for CRT based on conduction delays that lead to electrical and mechanical dyssynchrony of the left ventricle.
心脏再同步治疗(CRT)是治疗心力衰竭(HF)、左心室(LV)功能受损且QRS波群增宽患者的既定疗法。最初的随机临床试验促使CRT得到广泛应用,这些试验根据QRS波持续时间选择患者,而未关注QRS波形态。然而,最近的证据强调了左束支传导阻滞形态在接受CRT治疗患者中的作用,以便预测对治疗的更好反应。此外,传统的右心室心尖部起搏可能对心脏结构和左心室功能产生长期有害影响,可能导致心力衰竭的发生。因此,当前指南建议,对于心室起搏比例高(或预期高)且射血分数降低的患者,将传统起搏器或植入式心脏复律除颤器升级为CRT或CRT。我们基于导致左心室电和机械不同步的传导延迟,综述了目前关于CRT候选者选择的知识。